Skip to Main Content

WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of Sen. Bernie Sanders’ plans for drug pricing interrogations, he told STAT in an interview. But it will be a show.

The Vermont Independent is bringing executives from drugmakers Eli Lilly, Novo Nordisk, and Sanofi, along with pharmacy benefit managers Express Scripts, OptumRx, and CVS Health, to appear before the Senate Health, Education, Labor, and Pensions Committee this week.


“Now [it’s time] for Congress to think big, not small, and to tackle the fundamental issues as to why we pay so much for prescription drugs,” he said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.